论文部分内容阅读
目的:探讨尿激酶型纤溶酶原激活物(uPA)及其抑制物-1(PAI-1)在子宫内膜癌发生、发展中的作用。方法:子宫内膜癌标本61例,同时取患者相应的癌旁正常子宫内膜组织作为对照。应用组织芯片法与免疫组织化学法,检测每例子宫内膜癌标本和正常子宫内膜组织中uPA及其抑制物PAI-1的表达情况。结果:PAI-1在子宫内膜癌组织中的表达率为37.7%(23/61),在正常子宫内膜组织中的表达率为60.7%(37/61),两组间差异有统计学意义(χ2=6.428,P<0.05);PAI-1的表达与患者的年龄、组织类型、肿瘤组织学分级、淋巴结转移无关(均P>0.05),但与临床病理分期有关(P<0.05)。uPA在子宫内膜癌组织中的阳性表达率为42.6%(26/61),在正常子宫内膜组织中的阳性表达率为21.3%(13/61),两组间差异有统计学意义(χ2=6.369,P<0.05);uPA的表达与患者的年龄、组织类型、肿瘤组织学分级无关(均P>0.05),但与肿瘤临床病理分期和肿瘤淋巴结转移有关(P<0.05)。此外,uPA和PAI-1在子宫内膜癌中阳性表达差异无统计学意义(P>0.05)。结论:uPA和PAI-1的异常表达在子宫内膜癌的发生中有重要作用,PAI-1的低表达和uPA的高表达与子宫内膜癌临床病理进展有关。
Objective: To investigate the role of urokinase-type plasminogen activator (uPA) and its inhibitor-1 (PAI-1) in the pathogenesis and progression of endometrial carcinoma. Methods: 61 cases of endometrial cancer specimens, taking the corresponding normal endometrial cancer tissue as a control. Tissue microarray and immunohistochemistry were used to detect the expression of uPA and its inhibitor PAI-1 in each case of endometrial carcinoma and normal endometrium. Results: The positive rate of PAI-1 expression in endometrial carcinoma was 37.7% (23/61) and in normal endometrium was 60.7% (37/61), the difference was statistically significant (Χ2 = 6.428, P <0.05). The expression of PAI-1 was not related with the age, histological type, histological grade and lymph node metastasis (all P> 0.05) . The positive expression rate of uPA in endometrial carcinoma was 42.6% (26/61), and that in normal endometrium was 21.3% (13/61). The difference between the two groups was statistically significant ( χ2 = 6.369, P <0.05). The expression of uPA was not associated with the age, histological type and histological grade (all P> 0.05), but correlated with clinicopathologic stage and tumor lymph node metastasis (P <0.05). In addition, there was no significant difference in the expression of uPA and PAI-1 in endometrial carcinoma (P> 0.05). Conclusion: The abnormal expression of uPA and PAI-1 plays an important role in the pathogenesis of endometrial carcinoma. The low expression of PAI-1 and the high expression of uPA are associated with the clinicopathological progress of endometrial carcinoma.